```html

Chronic Hepatitis C – Comprehensive Medical Guide

Overview

Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) that primarily attacks the liver. When the infection persists for ≥6 months, it is classified as **chronic hepatitis C**. Over time, chronic inflammation can lead to scar tissue (fibrosis) and cirrhosis, increasing the risk of liver cancer.

Who it affects

• All ages and sexes can be infected, but the prevalence is highest among adults aged 20‑49.
• In the United States, an estimated 2.4 million people (≈0.7 % of the population) are living with chronic HCV [CDC, 2023].
• Globally, the World Health Organization estimates ~71 million people (≈1 % of the world population) have chronic hepatitis C [WHO, 2022].

Many individuals are unaware they are infected because the disease can remain silent for years. Early detection and modern antiviral therapy have dramatically improved outcomes.

Symptoms

During the acute phase (first 6 months) many people have no symptoms. When symptoms do appear, they are often nonspecific. As the infection becomes chronic, a broader set of signs may develop.

• Fatigue – persistent tiredness that does not improve with rest.
• Right‑upper‑quadrant discomfort – dull ache or fullness under the ribs where the liver sits.
• Jaundice – yellowing of the skin or eyes, indicating significant liver dysfunction.
• Dark urine and pale stools – result from impaired bilirubin excretion.
• Loss of appetite and unexplained weight loss.
• Nausea or vomiting – especially after meals.
• Muscle or joint aches – a common “flu‑like” manifestation.
• Itchy skin (pruritus) – due to bile salt buildup.
• Easy bruising or bleeding – a sign of reduced clotting factor production.
• Swelling in the legs or abdomen (edema, ascites) – indicates advanced liver disease.
• Spider angiomas – small, spider‑like blood vessels on the skin.
• Enlarged liver (hepatomegaly) or spleen (splenomegaly) – may be palpable on exam.

Because these symptoms overlap with many other conditions, laboratory testing is essential for a definitive diagnosis.

Causes and Risk Factors

How HCV is transmitted

• Blood‑to‑blood contact – the most common route. This includes sharing needles or syringes for injection drugs, receiving contaminated blood transfusions (especially before 1992 in the U.S.), or unsafe medical procedures.
• Percutaneous exposure – accidental needle sticks in health‑care settings.
• Mother‑to‑child transmission – occurs in ~5 % of births to HCV‑positive mothers.
• Sexual contact – risk is higher among men who have sex with men (MSM) and in the presence of HIV or other sexually transmitted infections.

Key risk factors

• People who inject drugs (PWID) – up to 60‑90 % prevalence in some studies.
• Recipients of hemodialysis or organ transplantation.
• Individuals with HIV infection.
• People who were incarcerated or have a history of prison tattoos.
• Birth before 1992 (pre‑screened blood).
• Unprotected sexual activity with an HCV‑positive partner.

Diagnosis

Diagnosis combines a review of risk factors, physical examination, and specific laboratory tests.

1. Serologic screening – anti‑HCV antibody test

Detects antibodies that develop 4‑10 weeks after exposure. A positive result indicates exposure but does not differentiate past cleared infection from active disease.

2. Confirmatory testing – HCV RNA assay

Polymerase chain reaction (PCR) or transcription‑mediated amplification (TMA) quantifies viral RNA. Detectable HCV RNA for ≥6 months confirms chronic infection.

3. Genotyping

Identifies the HCV genotype (1‑6). Genotype influences treatment duration and choice of antiviral regimen.

4. Liver evaluation

• Blood‑based fibrosis markers – e.g., APRI, FibroTest.
• Transient elastography (FibroScan) – non‑invasive measurement of liver stiffness.
• Liver biopsy – reserved for cases where non‑invasive tests are inconclusive.

5. Additional labs

Comprehensive metabolic panel, complete blood count, coagulation profile, and screening for hepatitis A and B, HIV, and other infections.

Treatment Options

Since 2014, direct‑acting antivirals (DAAs) have revolutionized therapy, offering cure rates >95 % with fewer side effects.

1. Direct‑acting antivirals (DAAs)

DAAs target specific steps in the HCV life cycle. Common regimens include:

• Sofosbuvir/Velpatasvir (Epclusa) – pan‑genotypic, 12 weeks.
• Sofosbuvir/Ledipasvir (Harvoni) – genotype 1, 4, 5, 6; 8‑12 weeks.
• Glecaprevir/Pibrentasvir (Mavyret) – pan‑genotypic; 8‑12 weeks.
• Elbasvir/Grazoprevir (Zepatier) – genotypes 1 and 4; 12‑16 weeks.

Most regimens are taken once daily with food, have minimal drug interactions, and do not require interferon or ribavirin (both associated with major side‑effects).

2. Treatment duration & monitoring

• Typical course: 8‑12 weeks; extended to 16 weeks for patients with cirrhosis or prior DAA failure.
• Monitoring: HCV RNA at baseline, at week 4 (optional), at end of treatment, and 12 weeks post‑treatment (SVR12). Sustained virologic response (SVR) = cure.

3. Management of advanced disease

• Cirrhosis – patients may need continued surveillance for hepatocellular carcinoma (HCC) even after cure.
• Liver transplantation – HCV recurrence used to be a major issue, but DAAs can clear infection before or after transplant.

4. Lifestyle & supportive care

• Alcohol abstinence – prevents further liver injury.
• Vaccination against hepatitis A and B (if not immune).
• Weight management and control of metabolic conditions (diabetes, NAFLD).

Living with Chronic Hepatitis C

Daily management tips

• Medication adherence – set daily reminders; use pill organizers.
• Regular follow‑up – labs every 12 weeks during therapy; post‑treatment imaging if cirrhosis.
• Balanced nutrition – high‑protein, low‑sugar diet; limit saturated fats.
• Stay hydrated – supports liver detoxification.
• Avoid hepatotoxins – over‑the‑counter acetaminophen >2 g/day, herbal supplements with unknown purity.
• Exercise – 150 minutes of moderate activity weekly improves insulin sensitivity and reduces fibrosis progression.
• Psychosocial support – join support groups; consider counseling for anxiety or stigma.

Monitoring for complications

Even after cure, individuals with advanced fibrosis or cirrhosis require:

• Ultrasound ± alpha‑fetoprotein every 6 months for HCC screening.
• Endoscopy for variceal surveillance if portal hypertension is present.
• Vaccination updates (influenza, COVID‑19) to reduce additional liver stress.

Prevention

• Never share needles, syringes, or drug‑cutting equipment.
• Use sterile equipment for tattoos, piercings, or medical procedures. Verify that facilities follow infection‑control standards.
• Practice safe sex – condoms reduce risk, especially for MSM and HIV‑positive partners.
• Screen blood products – all blood in high‑income countries is now screened; be cautious with transfusions in low‑resource settings.
• Mother‑to‑child – pregnant women with HCV should be offered antiviral therapy after delivery; no current recommendation for cesarean delivery solely for HCV.
• Education and harm‑reduction – needle‑exchange programs, opioid‑substitution therapy, and community outreach lower incidence.

Complications

If left untreated, chronic hepatitis C can lead to serious, sometimes life‑threatening problems:

• Cirrhosis – scarring that impairs liver function; may cause portal hypertension, ascites, hepatic encephalopathy, and variceal bleeding.
• Hepatocellular carcinoma (HCC) – risk increases 15‑20‑fold in cirrhotic patients; annual incidence 1‑4 %.
• Decompensated liver disease – jaundice, coagulopathy, renal dysfunction (hepatorenal syndrome).
• Extra‑hepatic manifestations – mixed cryoglobulinemia, membranous glomerulonephritis, type 2 diabetes, lymphoma, and cardiovascular disease.
• Reduced quality of life – chronic fatigue, depression, and social stigma.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. “Hepatitis C FAQs.” 2023. https://www.cdc.gov/hepatitis/hcv/index.htm
• World Health Organization. “Global Hepatitis Report 2022.” 2022. https://www.who.int/publications/i/item/9789241565702
• Mayo Clinic. “Hepatitis C.” 2024. https://www.mayoclinic.org/diseases-conditions/hepatitis-c/
• Cleveland Clinic. “Hepatitis C Treatment & Medications.” 2024. https://my.clevelandclinic.org/health/diseases/17373-hepatitis-c
• National Institutes of Health. “Guidelines for the Treatment of Hepatitis C.” 2023. https://www.hcvguidelines.org
• European Association for the Study of the Liver. “EASL Recommendations on Treatment of Hepatitis C 2023.” https://easl.eu/publications/easl-guidelines

```